

Certified



Corporation



Our commitments and actions
are continually measured and
communicated in a very transparent way.

We have commitments and concrete actions in 3 areas:



for our environment



for our patients




for our communities

Our challenge:



Carbon
neutral

We decided to significantly raise the bar
with our commitment to become
carbon neutral by 2035.



[Visit www.actionoverwords.org to find out more!](http://www.actionoverwords.org)



ACTION
OVER WORDS

Systematically improving our impact

We aim to constantly measure and **improve** our environmental **impact** with targeted initiatives that can restore well-being and natural balance. Soil, air and water are the three elements **we are committed to preserving.**



4.3

times
higher

Use of renewable
energy in 2020 vs 2019

> 50%
of Chiesi Group waste is recycled



+6%

increase in 2020 vs 2019

Taking a leading role towards a sustainable value chain

We feel it is important to engage all of our partners to do their part for the society.

That is why we deployed our **Code of Interdependence** to our suppliers to guide them in improving their social and environmental impact.



over 16,000

partners and suppliers in scope

Our commitment to reducing the carbon footprint of our inhalers is combined with the assurance that the most appropriate inhaler will continue to be available for each patient



Putting patients at the centre of our activities reaches beyond words.

This means the development of patient-oriented services.




Choosing to care for the most vulnerable people

In our Global Rare Disease business unit, which is newly created in 2019, we are developing treatment for **rare diseases**.

There are 70000 rare diseases, and every one of them is different, is complex and often long to diagnose, while meanwhile the condition of the patient is deteriorating.

From a prevalence point of view there are a few but it has a huge impact on their families.

So it's an important societal issue that we want to address and make the difference for the patients with such conditions.



Our commitment to the **most fragile patients**


In the field of neonatology, our flagship development is poractant alfa, a life saving product providing an effective replacement for the natural lung surfactant essential for normal breathing.

5.6

million premature
babies treated

~100

countries



most used
worldwide



Committed to improve the impact of our products through their entire **life cycle**

7 areas for evaluating sustainability improvements:



End of life
(eg. recycling)



Product re-design



Reusable components



Lower resource consumption for production



Green chemistry
(eg. APIs, excipients)



Impact on patients
(eg. Safety, no toxic substances etc)



Sustainable materials
(eg. FSC paper, for first and secondary packaging)

Concrete steps towards more sustainable materials for our products

Chiesi's pharmaceutical boxes
are now produced exclusively with
FSC paper

FSC* is an independent international
certification, specific for the forest sector
and products derived from forests, implying
a correct, transparent and responsible
management of natural resources.



Sustainability is possible thanks to innovation

Chiesi Group has developed a five-year 350 million € worth investment plan to launch on the market an innovative formulation that will significantly reduce the carbon footprint of spray inhalers (pMDI) used for asthma and Chronic Obstructive Pulmonary Disease (COPD).



For respiratory physicians, to be used in line with communication guidelines by Carbon Minimal Inhaler Project.

Our commitment to the low-resource countries

to improve the access to good quality neonatal care particularly in Sub-saharian African countries as well as the management of respiratory conditions in Latin America.



(Neonatal Essential Survival Technology)

Reduce neonatal mortality rates by improving the quality of neonatal care.



(Global Access to Spirometry Project)

Develop clinical skills for the diagnosis and management of chronic respiratory diseases, by introducing spirometry capacity and training activities.




7

low-resource

countries in which
Chiesi Foundation
operates

Supporting society and local territories during the COVID-19 global pandemic

Since the start of this global crisis, Chiesi has committed its resources and expertise to support the worldwide response effort.



530
organizations

supported, of
which over
300 hospitals

10.4
million €

worth of donations
totalled globally*

*Updated December 2020



B forward-looking



B impactful



B different